Skip to main content
. 2014 May 7;57(11):4569–4583. doi: 10.1021/jm500569h

Figure 4.

Figure 4

Assessment of estrogenic/antiestrogenic properties of the test compounds on inducing prolactin (Prl) gene’s mRNA expression in GH3 rat pituitary tumor cells. (A) Treatments of the GH3 cells with compounds alone. The fold change of the mRNA was first calculated using the ΔΔCt method. The corresponding 10–10 M E2 control values were considered as 100%, and all other treatments were calculated accordingly. (B) Treatments of the GH3 cells with compounds in combination with 10–9 M E2. The fold change of the mRNA was first calculated using the ΔΔCt method. The corresponding 10–10 M E2 control values were considered as 100%, and all other treatments were calculated accordingly.